STRESS TEST AND TREATMENT OF CHRONIC KIDNEY DISEASE
The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.
1 . A method for treating a patient at risk for having suffered kidney injury or kidney disease progression comprising:
(a) administering a compound to the patient, wherein the compound is a protoporphyrin or mesoporphyrin;
(b) measuring the response of the patient to the compound, wherein the response comprises increased level of expression of one or more anti-oxidant proteins, wherein the increased level of expression is observed after 4 hours after administration of the compound; and
(c) administering a therapy to the patient if the level of expression of the one or more anti-oxidant proteins is above a predefined level.
2 . The method of claim 1 , wherein the anti-oxidant proteins comprise one or more of HO-1, ferritin, p21, or NQO1.
3 . The method of claim 1 , wherein the level of expression of the one or more anti-oxidant proteins is measured before step (a), and the level of expression of the one or more anti-oxidant proteins measured in step (b) is compared to the level of expression measured before step (a).
4 . The method of claim 1 , wherein the patient is suffering from chronic kidney disease.
5 . (canceled)
6 . The method of claim 1 , wherein compound is a metal protoporphyrin.
7 . The method of claim 6 , wherein the metal protoporphyrin is tin, cobalt, or zinc protoporphyrin.
8 . The method claim 1 , wherein the dose of the compound is 9 mg or greater.
9 . The method of claim 1 , wherein the therapy comprises administering a potent antioxidant.
10 . The method of claim 1 , wherein the therapy comprises administering tetrahydrocurcumen.
11 - 18 . (canceled)
19 . The method of claim 1 , wherein the increased level of expression is observed after 12 hours after administration of the compound.
20 . The method of claim 1 , wherein the increased level of expression is observed after 24 hours after administration of the compound.
21 . The method of claim 1 , wherein the increased level of expression is observed after 48 hours after administration of the compound.
22 . The method of claim 1 , wherein the anti-oxidant proteins comprise NQ01.
23 . The method of claim 19 , wherein the anti-oxidant proteins comprise p21.
24 . The method of claim 20 , wherein the anti-oxidant proteins comprise ferritin.
25 . The method of claim 21 , wherein the anti-oxidant proteins comprise HO-1.